Sanofi Lipid 15
Version 1.d4cbc646 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | Sanofi Lipid 15 |
| Synonyms | Sanofi Lipid-15， Lipid15， Lipid 15 |
| SMILES | CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)N(CCCN(C)C)C(=O)CCC(=O)OC(CCC)CCCCCC |
| Formula | C58H108O7N2 |
| M.Wt | 945.51 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Reprogramming CD22 CAR-T cells in vivo Using CD8-Targeted mRNA-LNPs to Treat Hematological Malignancies. Mol Ther. 2026 Feb 13:S1525-0016(26)00106-1. doi: 10.1016/j.ymthe.2026.02.020. Epub ahead of print. PMID: 41691371. |
Lipid 15 is the lead ionizable cationic lipid (ICL) for CD8-targeted mRNA-LNPs. As the core LNP component, Lipid 15 yields ~100 nm uniform particles with near-neutral surface charge at physiological pH, while becoming strongly cationic in acidic endosomes—reducing hepatic off-target uptake and enabling efficient endosomal escape to release mRNA. Versus other ICL candidates, Lipid 15 achieves far higher mRNA transfection efficiency in primary human CD8⁺ T cells, supports robust transient CAR expression, and triggers minimal cytokine release in immunogenicity assays. It retains structural and functional stability after freeze storage. When formulated into anti-CD8 VHH-conjugated LNPs carrying CD22 CAR mRNA, Lipid 15 drives specific in vivo reprogramming of circulating CD8⁺ T cells into functional CAR-T cells, delivering potent tumor suppression in humanized hematological malignancy models without overt toxicity.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →